Roche to Acquire PathAI for $750M in AI Pathology Deal
Roche acquires PathAI for $750M to integrate AI pathology tools into its diagnostics division and clinical trial infrastructure for...
Navepegritide Shows 5.84 cm/year Growth Velocity in Achondroplasia Trial
Navepegritide shows 5.84 cm/year growth velocity in achondroplasia trial, nearly double placebo at week 52 with clean safety profile...
Vaxcyte’s VAX-31 Advances With Three Phase 3 Trials Enrolling 6,191 Adults
Vaxcyte's VAX-31 Phase 3 trials enroll 6,191 adults across three fully enrolled studies designed to challenge Prevnar 20 and...
Daraxonrasib Doubles Overall Survival in Second-Line Pancreatic Cancer
Daraxonrasib doubled overall survival in second-line metastatic pancreatic cancer versus chemotherapy in the RASolute 302 trial.
Aktis Oncology Initiates Phase 1b Trial of AKY-2519 in mCRPC
Aktis Oncology initiates Phase 1b trial of AKY-2519 in metastatic castration-resistant prostate cancer, targeting B7-H3 expression.
Zentalis Launches ASPENOVA Phase 3 Trial of Azenosertib in Platinum-Resistant Ovarian Cancer
Zentalis launches ASPENOVA Phase 3 trial of azenosertib in platinum-resistant ovarian cancer, targeting Cyclin E1-overexpressing tumors with a dual-track...
Dupixent Improves Esophageal Function in Phase 4 Eosinophilic Esophagitis Trial
Dupixent improves esophageal function in Phase 4 trial, achieving structural changes equivalent to dilation procedures without mechanical intervention.
Cellectar’s Iopofosine Meets FDA Durability Requirements in Waldenström Study
Cellectar's iopofosine meets FDA durability requirements in Waldenström study with 83.6% ORR and 17.8-month median response duration.
Nanobiotix Amends NANORAY-312 Trial Design, Eliminates Interim Analysis
Johnson & Johnson amends NANORAY-312 trial design, eliminating interim analysis and accelerating the final efficacy readout in head and...
Ersodetug Shows Strong Hypoglycemia Reductions in Congenital Hyperinsulinism Trial
Ersodetug shows 50-80% reductions in hypoglycemia time in congenital hyperinsulinism trial, with strong patient retention in open-label extension.